Positron Emission Tomography (PET) Nuclear Medicine Market Report 2026

Positron Emission Tomography (PET) Nuclear Medicine Market Overview

• Positron Emission Tomography (PET) Nuclear Medicine market size has reached to $13.16 billion in 2025 • Expected to grow to $25.7 billion in 2030 at a compound annual growth rate (CAGR) of 14.3% • Growth Driver: Impact Of Chronic Disease Prevalence On The PET Nuclear Medicine Market • Market Trend: Advancements In The PET Nuclear Medicine Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Positron Emission Tomography (PET) Nuclear Medicine Market?

Positron Emission Tomography (PET) nuclear medicine is a medical imaging method that employs radioactive materials to visualize and assess metabolic activities within the body. It uses a small amount of radioactive material called a radiotracer to detect changes at the cellular level, allowing doctors to diagnose diseases early. The main types of positron emission tomography (PET) nuclear medicines are F-18, RB-82, and others. F-18, or fluorine-18, is a radioactive isotope commonly used in positron emission tomography imaging. It is used for various procedures such as diagnostic procedures, single photon emission computed tomography procedures, positron emission tomography procedures, therapeutic procedures, beta emitter procedures, alpha emitter procedures, and brachytherapy procedures and is applied for oncology, cardiology, neurology, and others. It is used by several end users, including hospitals, diagnostic centers, and research institutes.

What Is The Positron Emission Tomography (PET) Nuclear Medicine Market Growth Forecast?

The positron emission tomography (pet) nuclear medicine market size is expected to see rapid growth in the next few years. It will grow to $25.7 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing investments in molecular imaging, rising demand for personalized medicine diagnostics, expansion of neurological imaging applications, advancements in radiotracer development, growing adoption of hybrid imaging systems. Major trends in the forecast period include increasing adoption of advanced radiotracers, growing use of pet imaging in oncology, rising integration of pet with ct and mri systems, expansion of precision diagnostic imaging applications, enhanced focus on early disease detection.

Global Positron Emission Tomography (PET) Nuclear Medicine Market Segmentation

1) By Type: F-18, Rb-82, Other Types 2) By Procedure: Diagnostic Procedures, Hybrid PET CT Procedures, Positron Emission Tomography Procedures, Therapeutic Procedures, Beta Emitter Procedures, Alpha Emitter Procedures, Targeted Radiopharmaceutical Therapy 3) By Application: Oncology, Cardiology, Neurology, Other Applications 4) By End User: Hospitals, Diagnostic Centers, Research Institutes Subsegments: 1) By F-18 (Fluorine-18): F-18 FDG (Fluorodeoxyglucose), F-18 NaF (Sodium Fluoride), F-18 Fluorocholine 2) By Rb-82 (Rubidium-82): Rb-82 for Myocardial Perfusion Imaging, Rb-82 for Cardiac PET Stress Testing, Rb-82 for Other Cardiac Applications 3) By Other Types: C-11 (Carbon-11), N-13 (Nitrogen-13), O-15 (Oxygen-15), Ga-68 (Gallium-68)

What Is The Driver Of The Positron Emission Tomography (PET) Nuclear Medicine Market?

The increasing prevalence of chronic diseases is expected to propel the growth of the positron emission tomography (PET) nuclear medicine market going forward. A chronic disease is a long-lasting health condition that typically persists for three months or more and may require ongoing medical attention or limit daily activities. The rise in chronic diseases is driven by factors such as an aging population, lack of physical activity, unhealthy eating habits, and environmental risks. PET nuclear medicine assists in managing chronic diseases by offering advanced imaging methods that enable early detection, precise diagnosis, and ongoing monitoring of these illnesses. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2050, over 35 million new cancer cases were projected, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of chronic diseases drives the growth of the positron emission tomography (PET) nuclear medicine industry.

Key Players In The Global Positron Emission Tomography (PET) Nuclear Medicine Market

Major companies operating in the positron emission tomography (pet) nuclear medicine market are Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Canon Medical Systems Corporation, Fujifilm Holdings Corporation, Shimadzu Corporation, Toshiba America Medical Systems Inc., Mediso Medical Imaging Systems Ltd., Lantheus Holdings Inc., Jubilant DraxImage Inc., Advanced Accelerator Applications, Eckert & Ziegler Strahlen- und Medizintechnik AG, Cardinal Health, NorthStar Medical Radioisotopes LLC, Bruker Corporation, Digirad Corporation, Neusoft Medical Systems Co. Ltd., Agfa HealthCare NV, Bayer AG, Positron Corporation

Global Positron Emission Tomography (PET) Nuclear Medicine Market Trends and Insights

Major companies operating in the positron emission tomography (PET) nuclear medicine market are developing technologically advanced products, such as PET slice scanners, to provide high-resolution images of metabolic activity. A PET slice scanner is a medical imaging device that combines positron emission tomography (PET) with advanced computing techniques to create detailed, cross-sectional images of metabolic processes in the body, allowing for detecting and monitoring diseases, particularly cancer. For instance, in July 2024, Positron Corporation, a US-based nuclear medicine company, launched the NeuSight PET-CT 3D 64-slice scanner. The NeuSight PET-CT 3D 64-slice scanner sets a new benchmark in imaging and diagnostic precision, combining advanced technology with patient comfort and operational efficiency. It is designed to transform cardiac PET imaging and offers exceptional value and performance at an unmatched price point, making it ideal for cardiology and oncology clinical studies. With superior data acquisition and innovative identification technology, the NeuSight PET-CT enhances scanning speed and accuracy, delivering comprehensive anatomic and functional imaging for heart, tumor, and brain studies across multiple molecular imaging applications.

What Are Latest Mergers And Acquisitions In The Positron Emission Tomography (PET) Nuclear Medicine Market?

In February 2023, Lantheus Holdings Inc., a US-based radiopharmaceutical company, acquired Cerveau Technologies Inc. for an undisclosed amount. This acquisition aligns with Lantheus's growth strategy by diversifying its radiopharmaceutical diagnostic imaging agent pipeline to include the most widely used Tau PET imaging agent for Alzheimer's disease. Additionally, it enhances its portfolio with an extensive array of academic collaborations and pharmaceutical partnerships. Cerveau Technologies Inc. is a US-based provider of F 18-labeled positron emission tomography imaging agent that targets Tau tangles in Alzheimer's disease.

Regional Outlook

North America was the largest region in the positron emission tomography (PET) nuclear medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Positron Emission Tomography (PET) Nuclear Medicine Market?

The positron emission tomography (PET) nuclear medicine market consists of sales of radiotracers, dose calibrators, injection systems, patient monitoring systems and simulation tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Positron Emission Tomography (PET) Nuclear Medicine Market Report 2026?

The positron emission tomography (pet) nuclear medicine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the positron emission tomography (pet) nuclear medicine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.